Pulmonary embolism response team (PERT) implementation and its clinical value across countries: a scoping review and meta-analysis

Lukas Hobohm1,2 · Ioannis T. Farmakis2 · Karsten Keller1,2,3 · Barbara Scibior2 · Anna C. Mavromanolii2 · Ingo Sagoschen1 · Thomas Münzel1 · Ingo Ahrens4 · Stavros Konstantinides2,5

Received: 28 April 2022 / Accepted: 29 July 2022 / Published online: 17 August 2022
© The Author(s) 2022

Abstract

Background Over the last years, multidisciplinary pulmonary embolism response teams (PERTs) have emerged to encounter the increasing variety and complexity in the management of acute pulmonary embolism (PE). We aimed to systematically investigate the composition and added clinical value of PERTs.

Methods We searched PubMed, CENTRAL and Web of Science until January 2022 for articles designed to describe the structure and function of PERTs. We performed a random-effects meta-analysis of controlled studies (PERT vs. pre-PERT era) to investigate the impact of PERTs on clinical outcomes and advanced therapies use.

Results We included 22 original studies and four surveys. Overall, 31.5% of patients with PE were evaluated by PERT referred mostly by emergency departments (59.4%). In 11 single-arm studies (1532 intermediate-risk and high-risk patients evaluated by PERT) mortality rate was 10%, bleeding rate 9% and length of stay 7.3 days [95% confidence interval (CI) 5.7–8.9]. In nine controlled studies there was no difference in mortality [risk ratio (RR) 0.89, 95% CI 0.67–1.19] by comparing pre-PERT with PERT era. When analysing patients with intermediate or high-risk class only, the effect estimate for mortality tended to be lower for patients treated in the PERT era compared to those treated in the pre-PERT era (RR 0.71, 95% CI 0.45–1.12). The use of advanced therapies was higher (RR 2.67, 95% CI 1.29–5.50) and the in-hospital stay shorter (mean difference −1.6 days) in PERT era compared to pre-PERT era.

Conclusions PERT implementation led to greater use of advanced therapies and shorter in-hospital stay. Our meta-analysis did not show a survival benefit in patients with PE since PERT implementation. Large prospective studies are needed to further explore the impact of PERTs on clinical outcomes.

Registration Open Science Framework 10.17605/OSF.IO/SBFK9.
Introduction

Acute pulmonary embolism (PE) is one of the most frequent cardiovascular emergencies and is of particular clinical relevance due to its life-threatening potential in case of cardiorespiratory decompensation [1]. Patients with acute PE constitute a heterogeneous group of patients, and therefore, the 2019 European Society of Cardiology (ESC) Guidelines emphasise the importance of risk stratification to define appropriate management strategies [2]. Over the last decade, the array of treatment options for PE has rapidly expanded; especially advanced treatment options, such as catheter-directed treatment, are increasingly attracting attention in the management of acute PE [3]. However, the increasing variety and complexity in treatment options and the need for implementation of tailored strategies raise the importance of interdisciplinary communication and collaboration.

The “heart team” concept for multidisciplinary management of patients with challenging cardiovascular diseases is meanwhile established and is gaining increasing acceptance worldwide [4]. Originating from the same conceptual framework, multidisciplinary rapid-response teams for the management of “severe” PE, known as pulmonary embolism response teams (PERTs), could help to optimise treatment for acute PE [5]. Members of the PERT meet in real time to ensure rapid clinical decision making and may include, depending on the local resources and expertise, specialists from cardiology, radiology, pulmonology, haematology, anaesthesiology and cardiothoracic surgery [6]. Little is known about the general composition and clinical value of PERT in daily clinical practice. We, therefore, conducted the present scoping review and meta-analysis to investigate the composition of PERTs across different countries and determine the added clinical value since its implementation.

Materials and methods

Study objectives

The objectives of the present scoping review and meta-analysis were: (1) to identify the published evidence regarding the implementation of PERTs in acute PE treatment, (2) to clarify the key characteristics in the structure, function and operating procedures of PERTs worldwide, and (3) to identify knowledge gaps concerning PERTs. The present review was performed according to the PRISMA extension guidelines for scoping reviews [7]. The protocol for this study has
been registered in the Open Science Framework (117605/OSF.IO/SBFK9).

**Data sources and searches**

A systematic search of MEDLINE (via PubMed), the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science was performed up to 10 January 2022. A search string was created for PubMed and modified accordingly for the other databases (Supplement 1). To complement our search, all references from selected studies were retrieved and manually reviewed according to the snowball effect. No language restrictions were set.

**Inclusion and exclusion criteria**

We considered full-text, prospective and retrospective observational studies, which included patients with acute PE evaluated by a PERT. Both controlled and uncontrolled (single-group) studies were eligible. In controlled studies, the (historical) control group consisted of patients with acute PE who were treated before the implementation of a PERT. Eligible articles were designed to either describe the structure and function of PERTs and/or to investigate outcomes related to the implementation of a PERT. The main outcome was all-cause mortality (overall, in-hospital or 30-day mortality). Additional outcomes were the occurrence of bleeding (overall and major bleeding), 30-day rehospitalisation rates, length of hospitalisation, use of intensive care unit (ICU), length of stay in the ICU, use of advanced therapies [comprising systemic full- or half-dose thrombolysis, catheter-directed treatment (CDT) including catheter-directed thrombolysis or percutaneous thrombectomy, surgical thrombectomy and extracorporeal membranous oxygenation (ECMO)]; the insertion of a vena cava [IVC] filter was also evaluated. We excluded case reports and non-peer-reviewed articles.

**Study selection**

Retrieved studies were imported into a reference management software (Mendeley version 1.19). After the removal of duplicated studies, two independent authors (IF, AM) at a first stage screened the titles and abstracts and at a second stage perused the full texts for eligible studies. A third author (LH) was consulted to resolve any discordance regarding eligibility of studies. All reasons for exclusion at the full-text study selection phase were reported.

**Data extraction and quality assessment**

We created a predefined excel spreadsheet into which two authors (IF, AM) independently extracted data from eligible studies. A pilot test was performed before the formal initiation of data extraction to ensure coherence. Any disagreement was resolved by consensus. We extracted data regarding the study design of each study (country of corresponding author, academic setting or not, multicenter or not, prospective or retrospective design, presence of control group or not, and population inclusion and exclusion criteria), site-specific characteristics of the PERT (structure and number of specialties involved, setting of PERT activations, proportion of patients with acute PE for whom PERT was activated, and predictors of PERT activation), baseline characteristics of the population (mean age, female sex, mean body mass index, active malignancy, right ventricular dysfunction, proportion of patients with low, intermediate–low, intermediate–high and high risk acute PE) and outcomes (as described above). We performed a quality assessment of the eligible controlled studies using the ROBINS-I risk-of-bias tool for non-randomised studies of interventions [8].

**Statistical analysis**

We performed a random effects model meta-analysis of controlled studies (DerSimonian and Laird method). The effect estimate was the risk ratio (RR) for binary outcomes and the mean difference for continuous outcomes, with corresponding 95% confidence intervals (CIs). Heterogeneity was assessed with the Cochran chi-square test and the I² statistic (values greater than 50% indicated high heterogeneity). A subgroup analysis was performed by only including patients with more severe PE (as defined per each study). Publication bias was assessed visually with the use of funnel plots. The analysis was performed using the meta package in R (version 3.6.3).

**Results**

**Description of studies**

The search strategy resulted in the retrieval of 292 studies after removal of duplicates. Among them, we identified 26 (8.9%) reviews, 17 (5.8%) letters or editorials and 39 (13.4%) conference abstracts related to PERT implementation. After the complete study selection process, 26 studies were included in the final review and meta-analysis (Fig. 1). Of them, 22 were original research studies and four were physician surveys. Results of physician surveys were extracted separately and are shown in Table S1 [9–12]. The majority of the 22 original research studies originated from the US, with the exception of one from Canada, Poland and Singapore, respectively [13–35]. All studies, except for one, were performed in an academic setting and three were multicentre. A total of 9823 patients were included in the
quantitative analysis. Characteristics of the included studies are presented in Table 1.

**Composition and operation of PERTs**

Overall, 31.5% of patients with acute PE were, irrespectively of their risk class, evaluated by a PERT across 8 studies [14, 16, 17, 24–27, 36]. The median number of specialties involved in PERT across all included studies was 6.5 (range 2–10). Up to 11 different specialties were involved in PERTs. The participating rate of each specialty is presented in Fig. 2, [5, 15, 16, 18, 19, 21, 23, 27, 29, 31, 33–35]. A single pager number, a dedicated phone line, or an alert via the electronic medical system were the tools for PERT activation across studies. Reasons for PERT activation, as reported in two studies, were the patient’s clinical presentation (particularly the presence of tachycardia, hypotension and hypoxia), right ventricular dysfunction, history of prior VTE or thrombophilia, family history of VTE, or presence of malignancy or recent surgery [26, 36]. Referrals originated mostly by emergency departments (59.4%), followed by medical or surgery wards (29.1%), and ICU (9.9%). Patients evaluated by a PERT had a mean age of 60 years; among these 48.7% were females, and 23.5% suffered from malignancy. Right ventricular dysfunction was present in 55% of the patients. In total, 74.5% were classified as having intermediate-risk PE and 16% as high-risk PE.

**Quality assessment of included controlled studies**

Nine controlled studies were assessed for risk of bias with the ROBINS-I tool; four of them were found to be of high risk of bias, while the rest of moderate risk of bias (Figure S1) [5, 14, 16, 17, 21, 25, 27, 33, 34]. A significant proportion of bias was identified in the bias due to confounding (44% of studies with high risk of bias). The “traffic light” plot for the risk of bias in each category of the individual studies is shown in Figure S2.
### Table 1 Characteristics of the included studies

| Study                  | Country | Population                          | Control | Number of patients | Age, years | Female, % | Cancer, % | RV Dysfunction, % | Risk groups, % |
|------------------------|---------|-------------------------------------|---------|--------------------|-----------|-----------|-----------|-------------------|----------------|
| Annabathula et al. 2021 [14] | US      | Acute PE (all-comers) exclusion criteria: no CTPA, no evaluation of the RV | Yes     | 530                | I: 58.1   | C: 59.5   | I: 53     | C: 58.4          | NR             |
| Araszkiewicz et al. 2021 [15] | Poland  | All PERT activations                 | No      | 680                | 57.7      | 50.6      | 21.2      | NR               | NR             |
| Carroll et al. 2020 [16]   | US      | Acute PE (all-comers)               | Yes     | 2042               | I: 63.6   | C: 62.3   | I: 53.9   | C: 52.3          | NR             |
| Chaudhury et al. 2019 [17]  | US      | Acute PE (all-comers) exclusion criteria: subsegmental PE, out-patient care | Yes     | 769                | I: 57.2   | C: 58.1   | I: 47.9   | C: 49.3          | NR             |
| Deadmon et al. 2017 [18]   | US      | All PERT activations                 | No      | 561                | 61.1      | 46.5      | 33.4      | NR               | NR             |
| Finn et al. 2021 [19]      | US      | PERT consultations before and after COVID-19 | No      | 100                | 59.2      | 45        | 11        | 47.6             | Intermediate and High: 65.7 |
| Groth et al. 2021 [20]     | US      | Acute PE, massive or submassive     | Yes     | 573                | I: 63.4   | C: 63.2   | I: 44.9   | NR               | NR             |
| Jen et al. 2020 [21]       | Singapore | Acute PE (all-comers)              | Yes     | 321                | I: 60.3   | C: 61.1   | I: 51.5   | C: 51.9          | NR             |
| Kendall et al. 2018 [35]   | US      | PE patients with massive or submassive PE and evaluated by PERT | No      | 40                 | 56        | 58        | 25        | NR               | Intermediate: 57, High: 43 |
| Khaing et al. 2019 [23]    | US      | PE patients evaluated by PERT      | No      | 52                 | 56        | 55.8      | 19.2      | NR               | Low: 0, Intermediate: 94.2, High: 5.8 |
| Kwok et al. 2021 [24]      | US      | Acute PE (all-comers) before and after COVID-19 | No      | 60                 |           |           |           | 43.3             | Low: 18.3, Intermediate: 76.6, High: 5 |
| Melamed et al. 2020 [25]   | US      | Acute PE (all-comers)              | Yes     | 728                | I: 62.4   | C: 62.4   | I: 47.7   | C: 52.4          | NR             |
| Study                        | Country | Population | Control | Number of patients | Age, years | Female, % | Cancer, % | RV Dysfunction, % | Risk groups, % |
|-----------------------------|---------|------------|---------|--------------------|------------|-----------|-----------|-------------------|----------------|
| Mortensen et al. 2021 [26]a | US      | Acute PE transferred to the ED | No      | NR                | 48.1       | 39        | NR        | Low: 56.9, Intermediate and High: 43.1 |
| Myc et al. 2020 [27]        | US      | Acute PE (all-comers) | Yes     | 554               | I: 61.9    | C: 62     | I: 48.1   | I: 36.3, NR       | I: Low: 35, Intermediate: 36.6, High: 28 C: Low: 30, Intermediate: 36.7, High: 33 |
| Parikh et al. 2021 [36]     | US      | PERT activations | No      | 69                | 60.3       | 47.8      | 20.3      | NR                | Low: 20.3, Intermediate: 65.2, High: 14.5 |
| Romano et al. 2020 [29]     | Canada  | PERT activations | No      | 128               | 63         | 42        | 32        | NR                | Low: 3.1, Intermediate: 85.2, High: 11.7 |
| Rosovsky et al. 2018 [5]a   | US      | Acute PE, eligible only those who met the hospital’s criteria for PERT activation | Yes     | 440               | I: 61      | C: 59     | I: 47     | I: 17, NR         | I: Low: 19.3, Intermediate: 49.1, High: 31.6 C: Low: 36.8, Intermediate: 31.6, High: 31.6 |
| Schultz et al. 2018 [17]d   | US      | PERT activations | No      | 416               | 61.2       | 50.2      | 26.7      | 55.5              | Low: 18.8, Intermediate: 69, High: 12.3 |
| Sista et al. 2018 [31]      | US      | PERT activations, massive or submassive | No      | 87                | 63.7       | 49.4      | 33.3      | NR                | Low: 0, Intermediate: 90.8, High: 9.2 |
| Wiske et al. 2020 [32]b     | US      | PERT activations | No      | 179               | 59.9       | 47.4      | 30.3      | 33                | Intermediate: 91.3, High: 8.7 |
| Wright et al. 2021 [33]b    | US      | PERT activations, massive or submassive | Yes     | 368               | I: 63.9    | C: 63.2   | I: 46     | I: 23, I: 84      | I: Low: 0, Intermediate–low: 36.8, Intermediate–high: 46.8, High: 16.5 C: Low: 0, Intermediate–low: 45.3, Intermediate–high: 28.5 High: 26.3 |
| Xenos et al. 2019 [34]      | US      | PERT activations | Yes     | 1069              | I: 58.5    | C: 56.6   | I: 45.5   | NR                | Intermediate–high: 87, High: 13 |

a studies from the Massachusetts general hospital
b studies from the university of Rochester medical center/strong memorial
c studies for the university Langone New York
d multicenter study comprising several centers included in this review. All studies with duplicated data were not pooled together to avoid unit-of-analysis error

C control population (not evaluated by PERT), CTPA computed tomography pulmonary angiogram, ED emergency department, I intervention population (evaluated by PERT), NR not reported, PE pulmonary embolism, PERT pulmonary embolism response team, RV right ventricle, VTE venous thromboembolism
Mortality regarding intermediate- and high-risk patients according to PERT implementation

Overall, 11 studies (n = 1532 patients) reported outcomes for the subgroup of intermediate- and high-risk patients who were evaluated by a PERT [5, 14, 16, 21, 23, 29, 31–35]. In this subgroup of patients, the pooled mortality rate reached 10% [177/1532 patients (95% CI 8–13%)], the pooled bleeding rate 9% [119/1221 patients (95% CI 7% to 12%)] and the mean length of stay was 7.3 days (95% CI 5.7–8.9 days). The use of any advanced therapy was high (393/1532 patients, 30%) and, in particular, 6% for systemic thrombolysis (89/1405 patients), 22% for CDT (266/1532 patients), 2% for surgical thrombectomy (21/986 patients) and 3% for ECMO (34/1018 patients); an IVC filter was inserted in 15% of patients (79/543 patients).

Clinical course of patients in the pre-PERT and PERT era

After pooling nine controlled studies, our meta-analysis comprised a total of 6,821 patients [5, 14, 16, 17, 21, 25, 27, 33, 34]. No difference in mortality was observed between the pre-PERT and PERT era when taking all risk classes into consideration (RR 0.89, 95% CI 0.67 to 1.19, Fig. 3A). When analysing patients with intermediate or high-risk PE only, the effect estimate for mortality were lower for patients treated in the PERT era compared to patients treated in the pre-PERT era; however, no statistical significance was achieved (RR 0.71, 95% CI 0.45–1.12, Fig. 3B). The heterogeneity among studies was high (I² = 63%, p < 0.01). The funnel plot indicated that studies with a larger number of patients showed a favourable effect of PERT implementation on mortality, whereas smaller studies were more likely to report a RR > 1.0 (Figure S3).

No differences in the 30-day readmission, bleeding (major and overall), and ICU admission rates were found in the whole population and in the subgroup of patients with intermediate or high-risk PE. However, the total length of hospital stay was lower in the PERT era compared to the pre-PERT era (MD − 1.61 days, 95% CI − 3.21 – − 0.02 days); this also applied to the length of stay in the ICU (MD −1.79 days, 95% CI − 3.29 – − 0.28 days). Heterogeneity was high (> 90%, p < 0.01) for both continuous outcomes.

Use of advanced therapies (pooled rate) was more frequent in the PERT era compared to the pre-PERT era (RR 2.67, 95% CI 1.29–5.50, I² = 95%, p < 0.01). For example, rates were higher for systemic thrombolysis [181/3242 (5.6%) in the PERT era vs. 79/2510 (3.1%) in the pre-PERT era; RR 1.70 (95% CI 0.73–3.98)] and CDT [214/3319 (6.4%) vs. 97/2000 (4.8%) in the pre-PERT era; RR 1.37 (95% CI 0.80–2.33)].
but not for surgical thrombectomy [22/2527 (0.9%) vs. 15/1967 (0.8%); RR 0.87 (95% CI 0.29–2.62)], or ECMO [31/2513 (1.2%) vs. 34/2819 (1.3%); RR 1.76 (95% CI 0.72–4.32)]. Use of IVC filters was less frequent in the PERT compared to the pre-PERT era [205/2132 (9.6%) vs. 233/1601 (14.6%); RR 0.67 (95% CI 0.56–0.80)].

Discussion

Acute PE is the most severe clinical manifestation of VTE; in case of haemodynamic instability, the short-term mortality rate ranges from 16 to 46% in patients with shock and from 52 to 84% in patients with cardiac arrest [1, 37]. The rationale behind the implementation of multidisciplinary PERT is to (1) improve the management of patients with life-threatening PE and (2) prevent cardiopulmonary arrest and death [38, 39]. Little is known about the effect of PERT implementation on clinical outcomes across different countries. To our knowledge, this is the first scoping review and meta-analysis addressing outcomes of patients with acute PE based on the availability of a PERT for clinical management and decision making.

The results of the present analysis indicate that the implementation of PERTs is a concept still predominantly implemented in the US. Even though the concept of PERT teams has been endorsed by the 2019 ESC Guidelines, only one study originated in Europe, notably in Poland, and reported on the composition and function of PERTs [15]. The rationale behind the implementation and structure of PERTs is based on the “heart team” concept, which facilitates patient management with a consensus opinion of different specialists and leads to improved organisation of teams and utilisation of resources [4]. In most cases, the number of PERT activations increased early after the implementation of PERT, suggesting both a learning curve and growing motivation of teams involved [17, 23]. In response to increasing treatment options for acute PE, each member of a PERT contributes with their own perspective based on their clinical and/or procedural expertise. A consensus recommendation by the National PERT Consortium™, established in 2015 in the US, suggests the composition of PERTs from specialists in the fields of cardiac surgery, cardiac imaging, interventional and non-interventional cardiology, critical care, emergency medicine, haematology, clinical pharmacy, pulmonary, diagnostic and interventional radiology, vascular medicine, and vascular surgery [40]. In our study, cardiologists or cardiac/vascular surgeons were included in all PERT activations, followed by pulmonologists or critical care physicians (92.9%) and radiologists (71.4%). Our results are in line with previous studies, in which substantial variations between institutions in terms of organisation, frequency of PERT activation and composition of PERTs were reported [41, 42]. The members of a PERT team should be adapted based on organisational and availability patterns in
The direct impact of PERTs on patient outcomes remains uncertain to date, since no direct prospective comparisons have been performed. In a retrospective singe-centre study, in which 769 patients with acute PE were divided in two groups corresponding to PE management in the pre-PERT and PERT era, all-cause 30-day mortality rate was significantly lower in patients treated in the PERT compared to the pre-PERT era (8.5% vs. 4.7%; \( p = 0.034 \)) [17]. In the present analysis, we found no differences in mortality between patients managed in the pre-PERT vs. the PERT era when taking all patients, regardless of PE risk class, into consideration. However, since the PERT concept aims to standardise the care of patients with severe PE, comparison of outcomes in low-risk patients is of limited clinical relevance in this context [43]. Even if some original studies included patients with acute low-risk PE evaluated by PERT [41], we focused on predictors used for PERT activation. Except for elevated troponin levels, also other parameters of right ventricular decompensation, such as hypoxia, high respiratory rate or mild hypotension, played a decisive role in the activation of PERT teams underlining the importance of PERTs particular for patients with severe PE [28]. In fact, only 3 out of 10 all-comers with PE are evaluated by a PERT [28, 44]; these are the patients for whom complex management decisions are needed. After including in the analysis only high-risk or intermediate-risk patients with PE, the effect estimate for mortality were lower, but not statistical significant for patients treated in the PERT era compared to patients treated in the pre-PERT era, likely due to small patient numbers.

Regardless of the risk class, length of the general and the ICU in-hospital stay was lower in the PERT era as compared to the pre-PERT era. Although the length of hospital stay may be considered a rather subjective outcome as the criteria for discharge were likely different across sites, our results suggest that the implementation of PERT in an institution may provide confidence for earlier discharge in stabilised patients with acute PE. Besides, among patients with intermediate risk PE, patients who undergo invasive therapies have been shown to have a shorter length of stay in the hospital [45]. The cost efficiency of the administrative costs for setting up a PERT vs. the expected cost reduction resulting from reduced hospitalisation duration and provision of more reasonable use of advanced treatment modalities remains to be investigated.

Treatment options for patients with acute PE have expanded [46]; thus a PERT should help to justify the optimal treatment approach in selected patients [17, 44]. A recent single-centre trend analysis demonstrated that PERT implementation resulted in more than a tenfold increase in the frequency of CDT use as compared to the period before the introduction of PERT [5]. Furthermore, Carroll et al. described comparable findings for increase in the use of CDT after PERT implementation [16]. Our meta-analysis indicates that PERT led to an approximately 2.5-fold increase in the use of advanced therapies, mostly driven by an increase in the use of CDT; this implies that the confidence of physicians in the use of advanced therapies is increasing. Except for CTD, systemic thrombolysis also was used more frequently after PERT implementation. Our analysis further showed that the increased use of advanced therapies in the PERT era does not appear to be accompanied by an increase in the rate of major bleeding. In this context, it needs to be mentioned that our analysis was not powered to show statistically significant differences in mortality rates between patients treated in the pre- and post-PERT era. Major randomised controlled trials, aiming to clinically validate catheter-directed modalities for intermediate-risk and high-risk PE, are currently ongoing [3] or are being planned. If positive, their results can be expected to further promote implementation of PERTs in the future.

Our study has some limitations. First, several of the included studies were post-hoc analyses of existing cohorts, hence the results are purely observational and no cause-and-effect relationship can be established. Second, conclusions regarding clinical outcomes cannot be made due to the fact that the numerical analysis was only explorative. Third, not all controlled studies reported the outcomes of subgroups with intermediate- and high-risk PE separately, which reduced the power of the numerical analysis. Finally, the definition of intermediate- and high-risk PE was not standardised across studies, contributing to heterogeneity in the analysis.

In conclusion, in our study we were able to analyse the association between PERT-based management and clinical outcomes in 9823 patients with acute PE. Our meta-analysis did not demonstrate an effect estimate on mortality in patients with intermediate- or high-risk PE of PERT implementation compared to the pre-PERT era. However, PERT implementation was associated with increasing use of advanced therapies and lower length of in-hospital stay. Our study should be considered hypothesis generating; large prospective observational studies are needed to further explore the impact of PERT teams on clinical outcomes and mortality in patients with acute PE.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00392-022-02077-0.

**Funding** Open Access funding enabled and organized by Projekt DEAL.
Data availability
The data underlying this article are available in the article and in its online supplementary material.

Declarations

Conflict of interest
L. Hobohm reports lecture/consultant fees from MSD and Janssen, outside the submitted work. I.T. Farmakis reports no conflicts of interest. K. Keller reports no conflicts of interest. B. Scibior reports no conflicts of interest. A. Mavromanolis reports no conflicts of interest. I. Sagosen reports no conflicts of interest. T. Münzel reports no conflict of interest. I. Ahrens reports personal lecture fees from Bayer Vital, Daiichi-Sankyo, Bristol-Meyers-Squibb, Pfizer and Boehringer. S.V. Konstantinides reports institutional grants and personal lecture/consultant fees from Bayer AG, Daiichi-Sankyo, and Boston Scientific; and personal lecture/consultant fees from Pfizer-Bristol-Myers Squibb and MSD, all outside the submitted work.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Keller K, Hobohm L, Ebner M, Kresoja KP, Munzel T, Konstantinides SV, Lankeit M (2020) Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur Heart J 41:522–529
2. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Menaveu N, Ni Aine F, Prandoni P, Frizkczysz P, Righini M, Torbicki A, Van Belle E, Zamorano JL, and Group ESCSD (2020) ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543–603
3. Hobohm L, Keller K, Munzel T, Gori T, Konstantinides SV (2020) EkoSonic(R) endovascular system and other catheter-directed treatment approaches for acute pulmonary embolism: overview of efficacy and safety outcomes. Expert Rev Med Devices 17:739–749
4. Holmes DR Jr, Rich JB, Zoghbi WA, Mack MJ (2013) The heart team of cardiovascular care. J Am Coll Cardiol 61:903–907
5. Rosovsky R, Chang Y, Rosenfield K, Channick R, Jaff MR, Weinberg I, Sundt T, Vitkin A, Rodriguez-Lopez J, Parry BA, Harshbarger S, Harinath P, Kabrhel C (2019) Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. J Thromb Thrombolysis 47:31–40
6. Dudzinski DM, Piazza G (2016) Multidisciplinary pulmonary embolism response teams. Circulation 133:98–103
7. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garrity C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Morta jy J, Clifford T, Tuncapel O, Straus SE (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467–473
8. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MA, Beutin L, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4019
9. Wang X, Ji QW, Rosenfield K, Tapson V, Nie SP (2021) Multidisciplinary pulmonary embolism response team in China: a nationwide survey. Respir Med 26:392–393
10. Todoran TM, Giri J, Barnes GD, Rosovsky RP, Chang YC, Jaff MR, Rosenfield K, Kabrhel C, and Consortium P (2018) Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the pulmonary embolism response team consortium. J Thromb Thrombol 46:39–49
11. Brailovsky Y, Kunchakarra S, Lakhter V, Barnes G, Masie D, Mancl E, Porcaro K, Bechara CF, Lopez JJ, Simpson K, Mathew V, Farea J, Darki A (2020) Pulmonary embolism response team implementation improves awareness and education among the house staff and faculty. J Thromb Thrombolysis 49:54–58
12. Barnes G, Giri J, Courtney DM, Naydenov S, Wood T, Rosovsky R, Rosenfield K, Kabrhel C (1995) Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT™ Consortium members. Hosp Pract 2017(45):76–80
13. [Recommendations of the Polish Gynecological Society expert panel on the use of Detromax in pregnancy]. Ginekol Pol 2015;86:962–5. PMID: 26995949
14. Annabathula R, Dugan A, Bhalla V, Davis GA, Smyth SS, Gupta VA (2021) Value-based assessment of implementing a pulmonary embolism response team (PERT). J Thromb Thrombolysis 51:217–225
15. Araszkiewicz A, Kurzyna M, Kopec G, Slawek-Szmyt S, Wrona K, Stepniewski J, Jankiewicz S, Pietrak S, Machowski M, Doro- ch a S, Mularek-Kubzda T, Torbicki A, Pruszczyk P, Roik M (2021) Pulmonary embolism response team: a multidisciplinary approach to pulmonary embolism treatment. Polish PERT Ini Rep Kardiol Polska 79:1311–1319
16. Carroll BJ, Beyer SE, Mehegan T, Dicks A, Pribish A, Locke A, Godishala A, Soriano K, Kanduri J, Sak K, Raber I, Wiest C, Balachandran I, Marcus M, Cha L, Hayes MM, Weinstein JL, Bauer KA, Secemsky EA, Pinto DS (2020) Changes in care for acute pulmonary embolism through a multidisciplinary pulmonary embolism response team. Am J Med 133:1313
17. Chaudhury P, Gadre S, Schneider E, Renapurkar R, Gomes M, Haddadin I, Heresi G, Tong MZY, Bartholomew JR (2019) Impact of multidisciplinary pulmonary embolism response team availability on management and outcomes. Am J Cardiol 124:1465–1469
18. Deadmon EK, Giordano NJ, Rosenfield K, Rosovsky R, Parry BA, Al-Bawardi FR, Chang YC, Kabrhel C (2017) Comparison of emergency department patients to inpatients receiving a pulmonary embolism response team (PERT) activation. Acad Emerg Med 24:814–821
19. Finn MT, Gogia S, Ingrassia JJ, Cohen M, Madhavan MV, Nouri SN, Breilovsky Y, Masoumi A, Fried IA, Uriel N, Agerstrad CI, Eisenberger A, Einstein AJ, Brodie D, Rosenzweig EB, Leon MB, Takeda K, Pucillo A, Takeda K, Pucillo A, Green P, Kirtane AJ, Parikh SA, Sethi SS (2021) Pulmonary embolism response team utilization during the COVID-19 pandemic. Vasc Med 26:426–433
20. Groth CM, Acquisto NM, Wright C, Marinescu M, McNitt S, Goldenberg I and Cameron SJ Pharmacists as members of an
interdisciplinary pulmonary embolism response team J Am Coll Clin Pharm. PMID: 35813573
21. Jen WY, Kristanto W, Teo L, Phua J, Yip HS, MacLaren G, Teoh K, Sim TB, Loh J, Ong CC, Chee YL, Kojodjojo P (2020) Assessing the impact of a pulmonary embolism response team and treatment protocol on patients presenting with acute pulmonary embolism. Heart Lung Circ 29:345–353
22. Kabrhel C, Rosovsky R, Channick R, Jaff MR, Weinberg I, Sundt T, Dudzinski DM, Rodriguez-Lopez J, Parry BA, Harshbarger S, Chang YC, Rosenfeld K (2016) A multidisciplinary pulmonary embolism response team initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary embolism. Chest 150:384–393
23. Khang P, Paruchuri A, Eisenbrey JR, Merli GJ, Gonsalves CF, West FM, Aware BK (1995) First year experience of a multidisciplinary pulmonary embolism response team with comparisons of outcomes between catheter directed therapy versus standard anticoagulation. Hosp Pract 20(48):23–28
24. Kwon B, Brosnanah SB, Amoroso NE, Goldenberg RM, Heyman B, Horovitz JM, Jamin C, Sista AK, Smith DE, Yuuriiditsky E, Maldonado TS (2021) Pulmonary embolism response team activation during the COVID-19 pandemic in a New York city academic hospital: a retrospective cohort analysis. J Thromb Thrombolysis 51:330–338
25. Melamed R, St Hill CA, Engstrom BI, Tierney DM, Smith CS, Agboto VK, Weise BE, Eckman PM and Skeik N (2020) Effects of a consensus-based pulmonary embolism treatment algorithm and response team on treatment modality choices, outcomes, and complications Clin Appl Thromb-Hemost 26. PMID: 32539524
26. Mortensen CS, Kramer A, Schulz JG, Giordano N, Zheng H, Andersen A, Nielsen-Kudsk JE and Kabrhel C Predicting factors for pulmonary embolism response team activation in a general pulmonary embolism population J Thromb Thrombolysis. PMID: 34370168
27. Myc LA, Solanki JN, Barros AJ, Muradin N, Nevalis MG, Earasi R, Richardson ED, Tsutsui SC, Enfield KB, Teman NR, Haskal ZJ, Mazzima S, Kennedy JLA, Miahalek AD, Sharma AM and Kadil A (2020) Adoption of a dedicated multidisciplinary team is associated with improved survival in acute pulmonary embolism Respi Res 21. PMID: 32571318
28. Parikh M, Chahine NM, Hammad TA, Tefera L, Li J, Carman T, Schilz R, Shishehbor MH (2021) Predictors and potential advantages of PERT and advanced therapy use in acute pulmonary embolism. Catheter Cardiovasc Interv 97:1430–1437
29. Romano KR, Cory JM, Ronco JJ, Legiehn GM, Bone JN, Finlayson GN (2020) Vancouver general hospital pulmonary embolism response team (VGH PERT): initial three-year experience. Canadian J Anesth-J Canadien D Anesth 67:1806–1813
30. Rosovsky R, Chang YC, Rosenfield K, Channick R, Jaff MR, Weinberg I, Sundt T, Witkin A, Rodriguez-Lopez J, Parry BA, Harshbarger S, Hariharan P, Kabrhel C (2019) Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis (vol 47, pg 31, 2019). J Thromb Thrombolysis 47:41–41
31. Sista AK, Friedman OA, Phua J, Yip HS, MacLaren G, Teoh K, Sim TB, Loh J, Ong CC, Chee YL, Kojodjojo P (2020) Assessing the impact of a pulmonary embolism response team and treatment protocol on patients presenting with acute pulmonary embolism. Heart Lung Circ 29:345–353
33. Wright C, Goldenberg I, Schleeed S, McNitt S, Gosei I, Elbadawi A, Pietropaoli A, Barrus B, Chen YL, Mazzillo J, Acquisto NM, Van Galen J, Hamer A, Marinescu M, Delehanty J, Cameron SJ (2021) Effect of a multidisciplinary pulmonary embolism response team on patient mortality. Am J Cardiol 161:102–107
34. Xenos ES, Davis GA, He Q, Green A, Smyth SS (2019) The implementation of a pulmonary embolism response team in the management of intermediate- or high-risk pulmonary embolism. J Vasc Surg-Ven-Lymph Disord 7:493–499
35. Kendall MR, Swadron S, Clavijo LC, Mehra AK, Hindoyan A, Matthews RV, Shavelle DM (2018) Us of the STEMI team for treatment of patients with pulmonary embolism: a pilot study. J Invas Cardiol 30:367–371
36. Parikh M, Chahine NM, Hammad TA, Tefera L, Li J, Carman T, Schilz R, Shishehbor MH (2021) Predictors and potential advantages of PERT and advanced therapy use in acute pulmonary embolism. Catheter Cardiovasc Intervent 97:1430–1437
37. Hobohm L, Sagochen I, Habertheuer A, Barso S, Valerio L, Wild J, Schmid FP, Gori T, Munzel T, Konstantinides S and Keller K (2021) Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolism Resuscitation. PMID: 34653550
38. Winters BD, Weaver SJ, Pfoh ER, Yang T, Pham JC, Dy SM (2013) Rapid-response systems as a patient safety strategy: a systematic review. Ann Intern Med 158:417–425
39. Mahar JH, Haddadin I, Sadana D, Gadre A, Evans N, Hornacek D, Mahal NF, Gomes M, Joseph D, Sehal M, Tong MZ, Bauer SR, Militello M, Silver B, Shishehbor M, Bartholomew JR, Heresi GA (2018) A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland clinic. J Thromb Thrombolysis 46:186–192
40. Rivera-Lebron B, McDaniel M, Ahkar K, Alrifai A, Dudzinski DM, Fanola C, Blais D, Janicke D, Melamed M, Mohrien K, Rozycyi E, Ross CB, Klein AJ, Peman NR, Yarboro L, Ichinose E, Sharma AM, Bartos JA, Elder M, Keeling B, Palevsky H, Naydenov S, Sen P, Amoroso N, Rodriguez-Lopez JM, Davis GA, Rosovsky R, Rosenfeld K, Kabrhel C, Horowitz J, Giri JS, Tapsen V, Channick R, and Consortium P (2019) Diagnosis, treatment and follow-up of acute pulmonary embolism: consensus practice from the PERT Consortium. Clin Appl Thromb Hemost 25:1076029619853037
41. Schulz J, Giordano N, Zheng H, Parry BA, Barnes GD, Heresi GA, Jaber W, Wood T, Todoran T, Courtney DM, Naydenov S, Khandhar S, Green P and Kabrhel C (2019) EXPRESS: a multidisciplinary pulmonary embolism response team (PERT) experience from a national multicenter consortium Pulm Circ 2045894018824563. PMID: 30632901
42. Barnes G, Giri J, Courtney DM, Naydenov S, Wood T, Rosovsky R, Rosenfeld K, Kabrhel C, National PCRC (1995) Nuts and bolts of running a pulmonary embolism response team: results from an observational survey of the national PERT consortium members. Hosp Pract 2017(45):76–80
43. Brailovsky Y, Lakhter V (2021) Pulmonary embolism response team: additional call burden or a valuable learning opportunity? J Am Coll Cardiol 77:1691–1696
44. Lacey MJ, Hammad TA, Parikh M, Tefera L, Sharma P, Kahl R, Zemko A, Li J, Carman T, Schilz R, Shishehbor MH (2021) Prospective experience of pulmonary embolism management and outcomes. J Invasive Cardiol 33:E173–E180
45. Sullivan AE, Holder T, Truong T, Green CL, Sofela O, Dahlan T, Granger CB, Jones WS and Patel MR (2020) Use of hospital resources in the care of patients with intermediate risk pulmonary embolism Eur Heart J Acute Cardiovasc Care. PMID: 33609111
46. Hobohm L, Schmidt FP, Gori T, Schmidtmann I, Barso S, Munzel T, Lankeit M, Konstantinides SV, Keller K (2021) In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism. Eur J Heart J Acute Cardiovasc Care 10:258–264